Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Long-term Depression01:05

Long-term Depression

33.2K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.2K
Long-term Depression01:03

Long-term Depression

3.3K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.3K
Freezing Point Depression and Boiling Point Elevation03:12

Freezing Point Depression and Boiling Point Elevation

39.9K
Boiling Point Elevation
The boiling point of a liquid is the temperature at which its vapor pressure is equal to ambient atmospheric pressure. Since the vapor pressure of a solution is lowered due to the presence of nonvolatile solutes, it stands to reason that the solution’s boiling point will subsequently be increased. Vapor pressure increases with temperature, and so a solution will require a higher temperature than will pure solvent to achieve any given vapor pressure, including one...
39.9K
Depressants01:28

Depressants

414
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
414
Depression: Overview01:18

Depression: Overview

870
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
870
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

475
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
475

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Union of Basic and Clinical Pharmacology. CXXII. Applying an objective evaluation to the status of class A orphan G protein-coupled receptors.

Pharmacological reviews·2026
Same author

G-protein regulatory network governs receptor internalization dynamics.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Longitudinal Phenotypic Trajectories in GNAO1-Related Disorders: Defining Disease Progression and Clinical Profiles.

Annals of neurology·2026
Same author

Updated BJP guidelines for transparent and rigorous natural product research.

British journal of pharmacology·2026
Same author

G protein regulatory network shapes magnitude and kinetics of behavioral responses in an engineered opioid receptor model.

The Journal of biological chemistry·2026
Same author

Conditional Modeling of GNAO1 Disorder Dissociates Circuit Specific Contributions to Pathology and Rationalizes Ameliorative Strategies.

Movement disorders : official journal of the Movement Disorder Society·2026

Related Experiment Video

Updated: Jan 28, 2026

Selection of Transporter-Targeted Inhibitory Nanobodies by Solid-Supported-Membrane SSM-Based Electrophysiology
09:12

Selection of Transporter-Targeted Inhibitory Nanobodies by Solid-Supported-Membrane SSM-Based Electrophysiology

Published on: May 3, 2021

3.0K

Targeting mGlyR with nanobodies for depression.

Thibaut Laboute1, Stefano Zucca2, Omar K Sial2

  • 1Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, Tours, France.

Nature Communications
|January 26, 2026
PubMed
Summary
This summary is machine-generated.

Researchers developed nanobodies targeting the glycine receptor mGlyR for depression treatment. Intranasal delivery in mice showed rapid, lasting antidepressant effects, offering a new biologic therapy for brain disorders.

More Related Videos

Live-cell Imaging of Endocytic Transport using Functionalized Nanobodies in Cultured Cells
08:02

Live-cell Imaging of Endocytic Transport using Functionalized Nanobodies in Cultured Cells

Published on: October 17, 2025

860
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.1K

Related Experiment Videos

Last Updated: Jan 28, 2026

Selection of Transporter-Targeted Inhibitory Nanobodies by Solid-Supported-Membrane SSM-Based Electrophysiology
09:12

Selection of Transporter-Targeted Inhibitory Nanobodies by Solid-Supported-Membrane SSM-Based Electrophysiology

Published on: May 3, 2021

3.0K
Live-cell Imaging of Endocytic Transport using Functionalized Nanobodies in Cultured Cells
08:02

Live-cell Imaging of Endocytic Transport using Functionalized Nanobodies in Cultured Cells

Published on: October 17, 2025

860
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.1K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biotechnology

Background:

  • Developing effective therapies for neuropsychiatric conditions like depression remains a significant medical challenge.
  • Traditional small molecule drugs often face limitations such as poor efficacy, off-target side effects, and target druggability issues.

Purpose of the Study:

  • To explore nanobodies as a novel biologic therapeutic approach for depression.
  • To develop selective nanobodies targeting the recently identified glycine receptor mGlyR, implicated in depression's pathophysiology.

Main Methods:

  • Generation of highly selective nanobodies against the mGlyR.
  • Assessment of antidepressant effects using a mouse model of stress-induced depression.
  • Structural biology (atomic structure determination) and cell-based assays to elucidate the mechanism of action.

Main Results:

  • Non-invasive intranasal delivery of the nanobody demonstrated rapid and sustained antidepressant effects in a mouse model.
  • The atomic structure of mGlyR bound to the nanobody was determined.
  • Mechanism of mGlyR modulation and its neural circuitry impact were revealed.

Conclusions:

  • Nanobodies targeting mGlyR represent a promising biologic strategy for treating depression.
  • This approach offers a potential alternative to small molecule drugs for intractable brain disorders.
  • Further development of nanobody-based therapies for neuropsychiatric conditions is supported by these findings.